Pub Date : 2024-05-14DOI: 10.29011/2574-3511.100208
{"title":"Saccharomyces boulardii CNCM I-745 for Prevention of Antibiotic-Associated Diarrhea and Clostridioides difficile in China: Systematic Review and Meta-Analysis","authors":"","doi":"10.29011/2574-3511.100208","DOIUrl":"https://doi.org/10.29011/2574-3511.100208","url":null,"abstract":"","PeriodicalId":91736,"journal":{"name":"Journal of digestive diseases and hepatology","volume":" 72","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141128443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-04DOI: 10.29011/2574-3511.100206
{"title":"Device-Measured Walking and Standing are Associated with Improved Quality of Life, Mental Health, and Biochemical Markers in Patients with Ulcerative Colitis: A Pilot Study","authors":"","doi":"10.29011/2574-3511.100206","DOIUrl":"https://doi.org/10.29011/2574-3511.100206","url":null,"abstract":"","PeriodicalId":91736,"journal":{"name":"Journal of digestive diseases and hepatology","volume":"18 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140743368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-19DOI: 10.29011/2574-3511.100204
{"title":"Periampullary Duodenal Diverticulitis – Another Cause for Acute Pancreatitis","authors":"","doi":"10.29011/2574-3511.100204","DOIUrl":"https://doi.org/10.29011/2574-3511.100204","url":null,"abstract":"","PeriodicalId":91736,"journal":{"name":"Journal of digestive diseases and hepatology","volume":"30 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140450938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-11DOI: 10.29011/2574-3511.100201
{"title":"Cholangiocarcinoma: A Literature Review","authors":"","doi":"10.29011/2574-3511.100201","DOIUrl":"https://doi.org/10.29011/2574-3511.100201","url":null,"abstract":"","PeriodicalId":91736,"journal":{"name":"Journal of digestive diseases and hepatology","volume":" 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139626812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-27DOI: 10.29011/2574-3511.100200
{"title":"Enhancing Hepatitis B Care Competency through Project ECHO: A Program Evaluation","authors":"","doi":"10.29011/2574-3511.100200","DOIUrl":"https://doi.org/10.29011/2574-3511.100200","url":null,"abstract":"","PeriodicalId":91736,"journal":{"name":"Journal of digestive diseases and hepatology","volume":"47 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139154550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-22DOI: 10.29011/2574-3511.100199
Ahmed Saeed, Omyma Ali, Khaled Abouhazima
This, an Odyssey of a previously healthy, 6 years old girl who was admitted at Sidra Hospital in Doha-Qatar and was treated initially for acute mastoiditis complicated with an epidural abscess and sagittal sinus thrombossis, she was treated with a long course of Ceftriaxone and then presented abruptly with acute pancreatitis due to obstructing biliary stones. No other known risk factors were identified. Little is reported in the literature about developing this full-blown presentation in this age group and this is to serve as a word for the wise and concerned
{"title":"Acute Obstructive Pancreatitis Secondary to Ceftriaxone Induced Cholelithiasis","authors":"Ahmed Saeed, Omyma Ali, Khaled Abouhazima","doi":"10.29011/2574-3511.100199","DOIUrl":"https://doi.org/10.29011/2574-3511.100199","url":null,"abstract":"This, an Odyssey of a previously healthy, 6 years old girl who was admitted at Sidra Hospital in Doha-Qatar and was treated initially for acute mastoiditis complicated with an epidural abscess and sagittal sinus thrombossis, she was treated with a long course of Ceftriaxone and then presented abruptly with acute pancreatitis due to obstructing biliary stones. No other known risk factors were identified. Little is reported in the literature about developing this full-blown presentation in this age group and this is to serve as a word for the wise and concerned","PeriodicalId":91736,"journal":{"name":"Journal of digestive diseases and hepatology","volume":"137 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139249687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-09DOI: 10.29011/2574-3511.100198
Francesco Baccelli, Erika Cantarelli, Lucia Del Vecchio, F. Labriola, F. Sbravati, Giulia Bardasi, Roberto Rondelli, P. Alvisi
Background: In last years, research interest increased for very early onset (VEO) inflammatory bowel disease (IBD), defined by age at diagnosis < 6 years. Previous works reported more severe disease course of VEO-IBD, compared with later-onset pediatric IBD, mainly attributed to a greater role of genetics in this age group. Otherwise, some studies questioned these results and reported comparable outcomes. Our study aimed to verify the effective role of age as a predictive factor of severity in the disease course. Methods: In this referral IBD single-center retrospective observational study , VEO-IBD was compared with IBD diagnosed between 6 and 17 years of age (ped-IBD). Patients with monogenic-IBD or IBD-like disease were excluded. We chose a minimum follow up period of 18 months since the diagnosis or any period in patients with Ulcerative Colitis (UC) who underwent surgery. The two cohorts were homogeneous for extension of disease and clinical severity at diagnosis and were compared for different clinical outcomes. Primary outcomes were the cumulative incidence of biological therapy use and the cumulative incidence of major surgery, as severity disease’ indices. Secondary outcomes were the cumulative incidence of clinical remission, steroid-dependence and the relapse free survival at the last follow up. Results: 29 VEO-IBD cases were compared with 52 ped-IBDs. Median follow up time was 4,9 years. UC were most represented in both groups (83% of VEO-IBD, 81% of ped-IBD). At the end of follow up, the surgical rate was significantly higher for VEO-UC group compared with ped-UC (p 0.018). No difference in biologic therapy use was detected (45,6% VEO-IBD vs 43,5% ped-IBD; p 0.72). Cumulative incidences of relapse free survival, steroid-dependence, use of immunosuppressive therapy and clinical remission at the end of follow up were comparable. Discussion: Our data question the evidence of a worse outcome of VEO-UC, in comparison with ped-UC. Notably, we demonstrate a higher need for surgery in VEO-UC.
{"title":"Outcome of Very Early Onset Pediatric Inflammatory Bowel Diseases Compared to Later-Onset Pediatric IBD: The 15-Year Single-Center Experience of a Referral Pediatric IBD Unit","authors":"Francesco Baccelli, Erika Cantarelli, Lucia Del Vecchio, F. Labriola, F. Sbravati, Giulia Bardasi, Roberto Rondelli, P. Alvisi","doi":"10.29011/2574-3511.100198","DOIUrl":"https://doi.org/10.29011/2574-3511.100198","url":null,"abstract":"Background: In last years, research interest increased for very early onset (VEO) inflammatory bowel disease (IBD), defined by age at diagnosis < 6 years. Previous works reported more severe disease course of VEO-IBD, compared with later-onset pediatric IBD, mainly attributed to a greater role of genetics in this age group. Otherwise, some studies questioned these results and reported comparable outcomes. Our study aimed to verify the effective role of age as a predictive factor of severity in the disease course. Methods: In this referral IBD single-center retrospective observational study , VEO-IBD was compared with IBD diagnosed between 6 and 17 years of age (ped-IBD). Patients with monogenic-IBD or IBD-like disease were excluded. We chose a minimum follow up period of 18 months since the diagnosis or any period in patients with Ulcerative Colitis (UC) who underwent surgery. The two cohorts were homogeneous for extension of disease and clinical severity at diagnosis and were compared for different clinical outcomes. Primary outcomes were the cumulative incidence of biological therapy use and the cumulative incidence of major surgery, as severity disease’ indices. Secondary outcomes were the cumulative incidence of clinical remission, steroid-dependence and the relapse free survival at the last follow up. Results: 29 VEO-IBD cases were compared with 52 ped-IBDs. Median follow up time was 4,9 years. UC were most represented in both groups (83% of VEO-IBD, 81% of ped-IBD). At the end of follow up, the surgical rate was significantly higher for VEO-UC group compared with ped-UC (p 0.018). No difference in biologic therapy use was detected (45,6% VEO-IBD vs 43,5% ped-IBD; p 0.72). Cumulative incidences of relapse free survival, steroid-dependence, use of immunosuppressive therapy and clinical remission at the end of follow up were comparable. Discussion: Our data question the evidence of a worse outcome of VEO-UC, in comparison with ped-UC. Notably, we demonstrate a higher need for surgery in VEO-UC.","PeriodicalId":91736,"journal":{"name":"Journal of digestive diseases and hepatology","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139321411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-06DOI: 10.29011/2574-3511.100097
Gastric cancer is one of the most common cancers worldwide being the 5th most common cancer and the 4th leading cause of cancer death. The most common type of gastric cancer is adenocarcinoma and is divided into two types; cardia and non-cardia gastric cancer. The incidence of non-cardia gastric cancer is declining due to the better detection and treatment of H. pylori which is one of its main risk factors. On the other hand, the incidence of the cardia type is rising due to the increase rate of obesity and gastroesophageal reflux disease. Worldwide, mass screening for gastric cancer is not currently implemented due to its variable incidence and cost effectiveness especially in low-risk countries. However, some countries with high incidence of gastric cancer have developed national screening programs which have led to better detection and reduction in mortality. There are different modalities that are approved for screening including upper endoscopy and photofluorography. Additionally, a few serum biomarkers have also been developed for screening which have promising results.
{"title":"Gastric Cancer Screening; Current Modalities and Strategies","authors":"","doi":"10.29011/2574-3511.100097","DOIUrl":"https://doi.org/10.29011/2574-3511.100097","url":null,"abstract":"Gastric cancer is one of the most common cancers worldwide being the 5th most common cancer and the 4th leading cause of cancer death. The most common type of gastric cancer is adenocarcinoma and is divided into two types; cardia and non-cardia gastric cancer. The incidence of non-cardia gastric cancer is declining due to the better detection and treatment of H. pylori which is one of its main risk factors. On the other hand, the incidence of the cardia type is rising due to the increase rate of obesity and gastroesophageal reflux disease. Worldwide, mass screening for gastric cancer is not currently implemented due to its variable incidence and cost effectiveness especially in low-risk countries. However, some countries with high incidence of gastric cancer have developed national screening programs which have led to better detection and reduction in mortality. There are different modalities that are approved for screening including upper endoscopy and photofluorography. Additionally, a few serum biomarkers have also been developed for screening which have promising results.","PeriodicalId":91736,"journal":{"name":"Journal of digestive diseases and hepatology","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134945383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-21DOI: 10.29011/2574-3511.100196
Bruno Barbosa Bandeira, Liliana Sampaio, Costa Mendes, Mayra Veloso, Ayrimoraes Soares, Wladimir Magalhães de Freitas, L. Casulari
Background: Liver cirrhosis is an important cause of morbidity and mortality especially if associated with malnutrition and sarcopenia. The accumulation of intramuscular fat, known as myosteatosis, generates an early changes in muscle architecture, quality and function and has also been considered a concept of sarcopenia by some authors. Sarcopenia implies an increase in hospital admissions and worse outcomes after liver transplants. Identifying sarcopenia early helps prevent these outcomes. Myosteatosis has been increasingly studied and its clinical significance in liver cirrhosis is still unclear. Objective: To know the prevalence of sarcopenia and myosteatosis in cirrhotic patients. Methods: Observational, cross-sectional study performed in a tertiary gastroenterology hospital from October 2018 to October 2020 in outpatients with liver cirrhosis to identify the presence of sarcopenia and myosteatosis and correlate with variables capable of predicting these situations. The patients were submitted to a number of tests including muscle strength, computed tomography analysis with evaluation of skeletal muscle index (SMI) and muscle attenuation coefficient (HU) at the level of the third lumbar vertebra (L3) and a 6-minute walk test for sarcopenia evaluation. Results: A total of 62 patients were studied, half of them male. Most participants were classified as CHILD-PUGH A (70.9%) and mean SMI of 25.78 kg/m 2 . The median MELD score was 11.5 points. The average force measured with a dynamometer was 27.59 kgf and for this exam, eight patients had demonstrated reduced muscle strength. The distance covered in six minutes in the patients walk test was on average 418.34 m ± 59.21. The average SMI assessed by CT at the level
{"title":"Sarcopenia and Myosteatosis in Cirrhotic Patients: A Cross-Sectional Study","authors":"Bruno Barbosa Bandeira, Liliana Sampaio, Costa Mendes, Mayra Veloso, Ayrimoraes Soares, Wladimir Magalhães de Freitas, L. Casulari","doi":"10.29011/2574-3511.100196","DOIUrl":"https://doi.org/10.29011/2574-3511.100196","url":null,"abstract":"Background: Liver cirrhosis is an important cause of morbidity and mortality especially if associated with malnutrition and sarcopenia. The accumulation of intramuscular fat, known as myosteatosis, generates an early changes in muscle architecture, quality and function and has also been considered a concept of sarcopenia by some authors. Sarcopenia implies an increase in hospital admissions and worse outcomes after liver transplants. Identifying sarcopenia early helps prevent these outcomes. Myosteatosis has been increasingly studied and its clinical significance in liver cirrhosis is still unclear. Objective: To know the prevalence of sarcopenia and myosteatosis in cirrhotic patients. Methods: Observational, cross-sectional study performed in a tertiary gastroenterology hospital from October 2018 to October 2020 in outpatients with liver cirrhosis to identify the presence of sarcopenia and myosteatosis and correlate with variables capable of predicting these situations. The patients were submitted to a number of tests including muscle strength, computed tomography analysis with evaluation of skeletal muscle index (SMI) and muscle attenuation coefficient (HU) at the level of the third lumbar vertebra (L3) and a 6-minute walk test for sarcopenia evaluation. Results: A total of 62 patients were studied, half of them male. Most participants were classified as CHILD-PUGH A (70.9%) and mean SMI of 25.78 kg/m 2 . The median MELD score was 11.5 points. The average force measured with a dynamometer was 27.59 kgf and for this exam, eight patients had demonstrated reduced muscle strength. The distance covered in six minutes in the patients walk test was on average 418.34 m ± 59.21. The average SMI assessed by CT at the level","PeriodicalId":91736,"journal":{"name":"Journal of digestive diseases and hepatology","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91525828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-19DOI: 10.29011/2574-3511.100094
Junjie Rao, Canyu Zhan, Jie Yang, Yurong Huang, Dongmei Chen, Sheng Wu, Gengqing Song
Helicobacter pylori (H. pylori) infection, a widespread global health concern, has traditionally been tackled with combinations of antibiotics and proton pump inhibitors (PPIs). While effective, these treatment regimens are frequently costly, complex
{"title":"Overcoming Antibiotic Resistance in Helicobacter Pylori: The Promise of Non-Antibiotic Therapies","authors":"Junjie Rao, Canyu Zhan, Jie Yang, Yurong Huang, Dongmei Chen, Sheng Wu, Gengqing Song","doi":"10.29011/2574-3511.100094","DOIUrl":"https://doi.org/10.29011/2574-3511.100094","url":null,"abstract":"Helicobacter pylori (H. pylori) infection, a widespread global health concern, has traditionally been tackled with combinations of antibiotics and proton pump inhibitors (PPIs). While effective, these treatment regimens are frequently costly, complex","PeriodicalId":91736,"journal":{"name":"Journal of digestive diseases and hepatology","volume":"38 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84441168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：